

■■■■■ (SPF Santé Publique - FOD Volksgezondheid)

From: ■■■■■ (SPF Santé Publique - FOD Volksgezondheid)
Sent: mardi, 28 février 2023 10:12
To: ■■■■■ (FOD Werkgelegenheid - SPF Emploi)
Cc: ■■■■■ (SPF Santé Publique - FOD Volksgezondheid); ■■■■■ (FOD Werkgelegenheid - SPF Emploi)
Subject: RE: BCR questions to 3M regarding PFAS and immune response
Attachments: RE: BCR questions to 3M regarding PFAS and immune response

Dag ■■■■■,

Nee helaas nog geen antwoord ontvangen, ik heb de mail vorige week woensdag verstuurd (sorry ik ben je vergeten in cc te zetten, zie bijlage voor de mail).

Groeten,
■■■■■

Van: ■■■■■ (FOD Werkgelegenheid - SPF Emploi) <■■■■■@werk.belgie.be>
Verzonden: lundi, 27 février 2023 15:11
Aan: ■■■■■ (SPF Santé Publique - FOD Volksgezondheid) <■■■■■@health.fgov.be>
CC: ■■■■■ (SPF Santé Publique - FOD Volksgezondheid) <■■■■■@health.fgov.be>; ■■■■■ (FOD Werkgelegenheid - SPF Emploi) <■■■■■@werk.belgie.be>
Onderwerp: RE: BCR questions to 3M regarding PFAS and immune response

Hallo ■■■■■,

Heeft 3M al iets laten weten?

Groeten,
■■■■■



FEDERALE OVERHEIDSDIENST
Werkgelegenheid, Arbeid
en Sociaal Overleg

Ernest Blerotstraat 1
1070 Brussel
werk.belgie.be



■■■■■ ■■■■■

Algemene Directie Humanisering van de Arbeid
Afdeling van de normen over het welzijn op het werk

■■■■■ ■■■■■

■■■■■@werk.belgie.be

From: ■■■■■ (SPF Santé Publique - FOD Volksgezondheid) <■■■■■@health.fgov.be>
Sent: woensdag 22 februari 2023 15:19
To: ■■■■■ (FOD Werkgelegenheid - SPF Emploi) <■■■■■@werk.belgie.be>
Cc: ■■■■■ (SPF Santé Publique - FOD Volksgezondheid) <■■■■■@health.fgov.be>
Subject: RE: BCR questions to 3M regarding PFAS and immune response

Dag [REDACTED],

Zie onderstaand een voorstel tot antwoord aan 3M met opnieuw de verzochte informatie.

Goed zo om naar hen te sturen? Laat maar weten als er nog andere zaken zijn die je graag toevoegt aan de “wishlist”



Groeten,

[REDACTED]

Dear [REDACTED],

Thank you for your response and the possibility to have a meeting to discuss the data and analysis of your paper.

After internal discussion we have concluded that it would be favorable to us to have the data before we have a meeting. This way we can be sure to properly analyze the data and formulate detailed questions, which could then be discussed during a potential meeting after [REDACTED]s.

Therefore we would like to underline that we require the following information in order to have an in depth analysis and fruitful discussion:

- The anonymized **raw data** that was used to perform the analyses in the abovementioned paper. This means the specific blood values of the enrollment and Follow-up visit per individual (of the 415 participants, but no medical history/information from the health history questionnaires is needed):
 - **PFAS-concentrations** for the 13 PFAS compounds (PFOS, PFOA, PFHxS, perfluorobutanoic acid [PFBA], perfluorobutanesulfonic acid [PFBS], perfluoropentanoic acid [PFPeA], perfluorohexanoic acid [PFHxA], perfluoroheptanoic acid [PFHpA], perfluorononanoic acid [PFNA], PFDA, 2-(N-methyl-perfluorooctane sulfonamido) acetic acid [MeFOSAA], 2-(N-Ethyl-perfluorooctane sulfonamido) acetic acid [EtFOSAA], and perfluorooctane sulfonamide [PFOSA]).
 - **Serum concentrations of antibodies against SARS-CoV-2:** Anti-spike IgG and neutralizing antibodies.

But also

- The **antigenic stimulus group** to which the participant belongs. To Anonymize these results you can just subdivide/rank the participants by group:

1. No COVID + 1 Pfizer vaccine
2. No COVID + 2 Pfizer vaccines
3. No COVID + 1 Moderna vaccine
4. No COVID + 2 Moderna vaccines
5. No COVID + J&J vaccine
6. Yes COVID + 1 Pfizer vaccine
7. Yes COVID + 2 Pfizer vaccines
8. Yes COVID + 1 Moderna vaccine
9. Yes COVID + 2 Moderna vaccines
10. Yes COVID + J&J vaccine
11. Yes COVID + no vaccine

Preferably, we would like to have these data in an **Excel spreadsheet**. As we ask for anonymized data and the specific medical history per individual is not needed, we are convinced that GDPR will not be an issue in this case.

- All of the correspondence regarding the submission of the manuscript with the journal where the paper was published (Environment International) or correspondence with other journals regarding previous submissions of

the same manuscript. By this we mean the **communication (mails, etc.) between the authors of the paper and the reviewers/editors** of the journal(s).

Many thanks in advance and hope to hear from you soon!

Kind regards
XXXX

De : [REDACTED]@mmm.com>

Envoyé : mardi, 14 février 2023 19:04

À : [REDACTED] (SPF Santé Publique - FOD Volksgezondheid) <[REDACTED]@health.fgov.be>

Cc : [REDACTED] <[REDACTED]@mmm.com>; [REDACTED] <[REDACTED]@mmm.com>; [REDACTED] <[REDACTED]@mmm.com>; [REDACTED] (SPF Santé Publique - FOD Volksgezondheid) <[REDACTED]@health.fgov.be>; [REDACTED] <[REDACTED]@mmm.com>

Objet : RE: BCR questions to 3M regarding PFAS and immune response

Dear [REDACTED],

Thank you for your most recent e-mail on February 9th. We are pleased to know that you have the corrected manuscript published by Environment International. As I mentioned in my prior e-mail, the only correction was in Figure 3a and 3b – there are no other corrections to the manuscript.

Regarding your request to examine the data, [REDACTED], who conducted the statistical analyses, are willing to meet with you. It would be quite helpful if you would send us a list of your specific analytic questions prior to our next meeting. I am sure they will try to conduct the specific analyses you are requesting as long as the analytic questions are very clear to them.

Unfortunately, between my schedule and their schedules, we will not be able to attend a conference call with you until after March 20th. Please for [REDACTED] several different dates and times. Please note that [REDACTED] will only be able to meet between 8:00 and 12:00 Eastern U.S. time.

I am copying [REDACTED] who will assist with coordinating the meeting from our end

Best regards

 Science.
Applied to Life.™

[REDACTED]
3M Corporate Occupational Medicine
3M Center, Building 220-6W-08 | St. [REDACTED], MN 55144-1000
Office: [REDACTED] | Mobile: [REDACTED] | Fax: [REDACTED]
[REDACTED]@mmm.com | www.3M.com

From: [REDACTED] (SPF Santé Publique - FOD Volksgezondheid) <[REDACTED]@health.fgov.be>

Sent: Thursday, February 9, 2023 10:00 AM

To: [REDACTED] <[REDACTED]@mmm.com>

Cc: [REDACTED] <[REDACTED]@mmm.com>; [REDACTED] <[REDACTED]@mmm.com>; [REDACTED] <[REDACTED]@mmm.com>; [REDACTED] (SPF Santé Publique - FOD Volksgezondheid) <[REDACTED]@health.fgov.be>

Subject: [EXTERNAL] RE: BCR questions to 3M regarding PFAS and immune response

Dear [REDACTED],

Apologies for the delay in our answer but it was difficult to identify suitable dates for a follow up discussion .
Would it be feasible for you and your team on 8 March , 9 March(pm) or 10March (am) CET.

Thank you in advance for your availability for a second discussion.
Kind regards,

██████████ on behalf of the BCR.

De : ██████████ <██████████@mmm.com>

Envoyé : mercredi, 11 janvier 2023 18:07

À : ██████████ (SPF Santé Publique - FOD Volksgezondheid) <██████████@health.fgov.be>

Cc : ██████████ <██████████@mmm.com>; ██████████ <██████████@mmm.com>; ██████████
<██████████@mmm.com>

Objet : RE: BCR questions to 3M regarding PFAS and immune response

Dear ██████████,

There was an error in Figure 3 of our published paper that I submitted as pre-read to your committee; "Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances", by Anna Porter, Sarah Kleinschmidt, Kara Andres, Courtney Reusch, Ryan M. Krisko, ██████████ A. ██████████, Geary W. Olsen, and Matthew P. Longnecker.

The first two graphs in the figure, 3a and 3b, are incorrect due to a copy and paste error (of PFNA rather than PFOS). We have contacted the journal and the editor has replaced the content of Figure 3 that was published. The link to the corrected paper is included below for your reference; please feel free to share the new link with interested members of your committee.

<https://www.sciencedirect.com/science/article/pii/S0160412022004640/pdf?isDTMRedir=true>

Please note that the only ██████████s are in Figure 3a and 3b - the other pieces of the figure (3c – 3h) and the caption remain the same. The corrected Figure 3a and 3b do not ██████████ the data analyses or the conclusion of the paper, which, as explained in the text of the manuscript (see last paragraph on page 5, continued on page 6) states "...results were consistent with a linear relationship. "

Regarding your request to examine the data, given the data analysis was performed by independent investigators from ██████████ (both are co-authors of the paper), I propose setting up a meeting with interested members of your committee and the biostatisticians and other investigators to understand and discuss the further analysis that may be of interest.

Thank you



██████████
3M Corporate Occupational Medicine
3M Center, Building 220-6W-08 | St. ██████████, MN 55144-1000

██████████@mmm.com | www.3M.com

3M Corporate Occupational Medicine
3M Center, Building 220-6W-08 | St. [REDACTED], MN 55144-1000
[REDACTED]
[REDACTED]@mmm.com | www.3M.com

From: [REDACTED] [REDACTED] (SPF Santé Publique - FOD Volksgezondheid) <[REDACTED].[REDACTED]@health.fgov.be>
Sent: Wednesday, December 21, 2022 6:09 AM
To: [REDACTED] [REDACTED] <[REDACTED]@mmm.com>
Cc: Reach (SPF Santé Publique - FOD Volksgezondheid) <[REDACTED]@health.fgov.be>; [REDACTED] [REDACTED]
<[REDACTED]@mmm.com>; [REDACTED] [REDACTED] <[REDACTED]@mmm.com>; [REDACTED] [REDACTED] <[REDACTED]@mmm.com>
Subject: [EXTERNAL] BCR questions to 3M regarding PFAS and immune response

Dear [REDACTED]. [REDACTED],

Following up on your presentation in the BCR 'open' meeting on the 12th of December 'A Study of COVID 19 in Relation to Serum Concentrations of Per and Polyfluoroalkyl Substances (PFAS)', we would like to receive some additional information.

It has come to our attention that [the paper you presented](#) at our meeting contains some errors. We would like to examine the data of this paper in some more detail, but the [supplementary data provided with the paper](#) does not allow for detailed calculations.

Therefore, we would like to receive some additional information:

- The anonymized **raw data** that was used to perform the analyses in the abovementioned paper. This means the specific blood values of the enrollment and Follow-up visit per individual (of the 415 participants, but no medical history/information from the health history questionnaires is needed):
 - **PFAS-concentrations** for the 13 PFAS compounds (PFOS, PFOA, PFHxS, perfluorobutanoic acid [PFBA], perfluorobutanesulfonic acid [PFBS], perfluoropentanoic acid [PFPeA], perfluorohexanoic acid [PFHxA], perfluoroheptanoic acid [PFHpA], perfluorononanoic acid [PFNA], PFDA, 2-(N-methyl-perfluorooctane sulfonamido) acetic acid [MeFOSAA], 2-(N-Ethyl-perfluorooctane sulfonamido) acetic acid [EtFOSAA], and perfluorooctane sulfonamide [PFOSA]).
 - **Serum concentrations of antibodies against SARS-CoV-2:** Anti-spike IgG and neutralizing antibodies.

But also

- The **antigenic stimulus group** to which the participant belongs. To Anonymize these results you can just subdivide/rank the participants by group:
 1. No COVID + 1 Pfizer vaccine
 2. No COVID + 2 Pfizer vaccines
 3. No COVID + 1 Moderna vaccine
 4. No COVID + 2 Moderna vaccines

5. No COVID + J&J vaccine
6. Yes COVID + 1 Pfizer vaccine
7. Yes COVID + 2 Pfizer vaccines
8. Yes COVID + 1 Moderna vaccine
9. Yes COVID + 2 Moderna vaccines
10. Yes COVID + J&J vaccine
11. Yes COVID + no vaccine

Preferably, we would like to have these data in an **Excel spreadsheet**. As we ask for anonymized data and the specific medical history per individual is not needed, we are convinced that GDPR will not be an issue in this case.

- All of the correspondence regarding the submission of the manuscript with the journal where the paper was published (Environment International) or correspondence with other journals regarding previous submissions of the same manuscript. By this we mean the **communication (mails, etc.) between the authors of the paper and the reviewers/editors** of the journal(s).

We hope you can provide us with this information, so we can evaluate the results of your paper more in depth.

We thank you for your cooperation.

██████████ (On behalf of the BCR)

████████████████████
DG Environment | Department of Product Policy and Chemical Substances
Avenue Galilée , 5 – 1210 Brussels | Belgium

████████████████████
 Federal Public Service
Health, Food Chain Security and Environment www.health.belgium.be

De FOD Werkgelegenheid, Arbeid en Sociaal Overleg respecteert de privacy-wetgeving, lees meer op <https://werk.belgie.be/nl/over-de-fod/bescherming-van-persoonsgegevens>

Indien dit bericht niet voor u bestemd is, verzoeken wij u dit aan ons te melden en het te vernietigen.
